AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AZN
- Rev/Share 18.2261
- Book/Share 14.4548
- PB 5.3184
- Debt/Equity 0.7343
- CurrentRatio 0.8629
- ROIC 0.1094
- MktCap 237821953900.0
- FreeCF/Share 2.8142
- PFCF 27.2607
- PE 28.6717
- Debt/Assets 0.2921
- DivYield 0.0204
- ROE 0.1984
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AZN | Exane BNP Paribas | -- | Outperform | -- | $75 | April 15, 2025 |
| Upgrade | AZN | UBS | Neutral | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | AZN | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Sept. 13, 2024 |
News
AstraZeneca shares leap with FDA set to review drug to treat breast cancer
Published: October 01, 2025 by: Market Watch
Sentiment: Positive
AstraZeneca shares rallied on Wednesday after the U.K. giant and its Japanese partner said the Food and Drug Administration was reviewing one of its drugs to treat breast cancer.
Read More
AstraZeneca's US listing may pull other firms from London in its wake
Published: September 30, 2025 by: Reuters
Sentiment: Negative
AstraZeneca's move to upgrade its listing in the U.S. risks pulling liquidity away from London's stock market and could pave the way for other large companies to follow suit, analysts, investors and advisers said.
Read More
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products puts over 50% of its free cash flow at risk, despite ongoing U.S. manufacturing expansion. Sanofi's high-margin Dupixent and AZN's broad U.S. portfolio are also vulnerable, though both are investing in U.S. production to seek exemptions.
Read More
AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices
Published: September 26, 2025 by: WSJ
Sentiment: Negative
AstraZeneca said it will offer its asthma and diabetes drugs at an up to 70% discount in the U.S. ahead of a Trump administration deadline for pharmaceutical companies to cut drug prices.
Read More
AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
Published: September 26, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery. AstraZeneca Direct will support people living with chronic conditions such as asthma, diabetes, heart failure and chronic kidney disease, and people seeking flu protection. Starting October 1, 2025, eligible patients with prescrip.
Read More
AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.
Read More
AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.
Read More
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Astrazeneca (AZN) is a Strong Value Stock
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca wins CHMP backing for label expansions of Koselugo in adult NF1 PN patients and Tezspire in chronic rhinosinusitis with nasal polyps.
Read More
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
Published: September 22, 2025 by: Benzinga
Sentiment: Positive
AstraZeneca Plc AZN and Amgen Inc.'s AMGN Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
3 Potential Biotech Acquisition Targets
Published: September 19, 2025 by: Seeking Alpha
Sentiment: Positive
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have good balance sheets. The article below discusses three promising names that have bright futures but also could attract interest from larger names in the industry.
Read More
AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy
Published: September 19, 2025 by: Seeking Alpha
Sentiment: Positive
AstraZeneca PLC is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. AZN's financials show improving margins, rising EPS, and efficient R&D investment, supporting steady share price appreciation and dividend growth. The company is fairly valued, possibly slightly undervalued, with a buy rating for long-term, lower-risk investors; shares below $70 would be a Strong Buy.
Read More
PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Negative
AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.
Read More
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
Published: September 17, 2025 by: Benzinga
Sentiment: Negative
AstraZeneca Plc AZN released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).
Read More
UK drug giants in the spotlight as part of latest sector review
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
The UK's two big drugmakers came under the spotlight in Berenberg's latest review of the pharmaceuticals sector. AstraZeneca PLC (LSE:AZN) gets a clear thumbs-up with a 'buy' rating and price target of £142, implying around 24% upside from £114.
Read More
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca's SAPHNELO® (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo.1 The safety profile observed in the interim analysis was consistent with the known clinical profile of SAP.
Read More
AstraZeneca lupus drug Saphnelo shows promise in self-injection trial
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) has reported positive results from a late-stage study of Saphnelo, its treatment for systemic lupus erythematosus (SLE), showing the drug was effective when given as a self-administered injection under the skin. The phase III TULIP-SC trial met its main goal at an interim analysis, demonstrating that patients receiving subcutaneous Saphnelo had a statistically significant and clinically meaningful reduction in disease activity compared with placebo.
Read More
AstraZeneca's asthma drug fails main goal of COPD study
Published: September 17, 2025 by: Reuters
Sentiment: Negative
AstraZeneca said on Wednesday that its asthma drug Fasenra failed the main goal of a late-stage study in patients with chronic obstructive pulmonary disease (COPD).
Read More
Exclusive: AstraZeneca pauses $270 million investment in Britain
Published: September 12, 2025 by: Reuters
Sentiment: Negative
Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Britain.
Read More
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
AstraZeneca's Baxdrostat makes its case
Published: September 01, 2025 by: Proactive Investors
Sentiment: Positive
Among the noise of tariffs, drug pricing reforms, and shifting investor sentiment, AstraZeneca PLC (LSE:AZN) has quietly delivered a clear result: its experimental blood pressure treatment, baxdrostat, works
Read More
Polaris Pharmacy Services Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service—The World's First At-Home Nasal Spray Flu Vaccine
Published: August 21, 2025 by: Business Wire
Sentiment: Neutral
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Pharmacy Services, a leading provider of long-term care and specialty pharmacy solutions, has been selected as the exclusive U.S. distributor for FluMist® Home, AstraZeneca's at-home flu vaccine service available for the 2025-2026 flu season. Through FluMist Home, individuals can order FluMist online to be delivered directly to their home on a date they choose—no doctor's visit or needle required. The program is the first of its kind to receive FD.
Read More
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.
Read More
AstraZeneca: Great Portfolio, But Not A Great Price
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Positive
AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and Ultomiris show impressive growth, but looming patent expiries and legal risks threaten future revenues. Heavy R&D investment and strategic moves into cell/gene therapy and AI-driven drug discovery support AstraZeneca's long-term growth outlook.
Read More
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
Read More
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
3 Of The Best SWANs On My Shopping List
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Positive
Our picks for today are MercadoLibre, Vulcan Materials, and AstraZeneca, with each providing a mix of value and growth. MercadoLibre is Latin America's leading e-commerce and fintech platform with increasing e-commerce penetration rates and economic growth driving its macro growth story. Vulcan Materials is the largest U.S. producer of construction aggregates, making it a beneficiary of U.S. infrastructure spending.
Read More
Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana
Published: July 30, 2025 by: Business Wire
Sentiment: Neutral
ACCRA, Ghana--(BUSINESS WIRE)-- #AfricaHealth--The strategic partnership between AstraZeneca and Revna Biosciences is rapidly transforming the landscape of lung cancer care in Ghana. Since the initial announcement in April 2025, the collaboration has made remarkable progress in improving the patient journey—from early diagnosis to molecular testing and now, access to life-saving treatment. In a landmark development, AstraZeneca launched one of their targeted therapies for EGFR mutated Lung Cancer patients in G.
Read More
AstraZeneca gets clean bill of health from leading investment bank
Published: July 30, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) shares have caught the attention of UBS, which reiterated its 'buy' rating and raised its price target to 14,200p, implying over 27% upside from the current level, after a solid set of second-quarter results. The drugmaker beat the Swiss Bank's estimates on both sales and operating profit, helped by stronger-than-expected growth in US oncology and a rebound in its rare disease division.
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Pascal Claude Roland Soriot
- Employees 94300